Magnesium hydroxide
ALIMENTARY TRACT AND METABOLISM
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Magnesium hydroxide is a drug catalogued in DrugCentral. It was first approved by the FDA in 2000. Recorded indications include Constipation, Gastric Hypersecretory Conditions, Gastroesophageal reflux disease and Heartburn.
- Indications: Constipation, Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn and Heartburn Prevention and others.
- ATC code: A02AA04 (Magnesium compounds).
- Molecular formula: H2MgO2; molecular weight 58.32 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (9)
- Constipation
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Heartburn
- Heartburn Prevention
- Hiatal Hernia with Reflux Esophagitis
- Incomplete passage of stool
- Indigestion
- Peptic ulcer
Off-label uses (14)
- Duodenal ulcer disease
- Dyspepsia Prevention
- Gastric ulcer
- Hypocalcemia
- Maintenance of Healing Duodenal Ulcer
- Multiple endocrine adenomas
- Osteoporosis
- Postmenopausal osteoporosis
- Prevention of Stress Ulcer
- Renal Osteodystrophy with Hyperphosphatemia
- Stress-Related GI Mucosal Bleeding Prevention
- Systemic mast cell disease
- Upper gastrointestinal hemorrhage
- Zollinger-Ellison syndrome
Contraindications (19)
- Aluminum intoxication
- Appendicitis
- Chronic diarrhea
- Dehydration
- Diarrhea
- Disease of liver
- Fecal impaction
- Gastrointestinal obstruction
- Hemorrhoids
- Hypercalcemia
- Hypermagnesemia
- Hyperparathyroidism
- Hypophosphatemia
- Impaired renal function disorder
- Kidney disease
- Kidney stone
- Malignant tumor of stomach
- Osteolysis
- Sarcoidosis
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2000-10-16 | FDA | — | MCNEIL CONS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A02AA04 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › ANTACIDS › Magnesium compounds |
G04BX01 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Other urologicals |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Sedation complication | 1266.0 |
| Creatinine renal clearance decreased | 1250.7 |
| Blood calcium decreased | 1088.3 |
| Orthostatic hypotension | 1060.9 |
| Sedation | 970.1 |
| Cognitive disorder | 959.0 |
| Balance disorder | 812.3 |
| Depressed level of consciousness | 680.8 |
| Constipation | 441.1 |
| Hypotension | 366.5 |
| Fall | 359.0 |
| Mobility decreased | 347.6 |
Chemical structure
| Molecular formula | H2MgO2 |
|---|---|
| Molecular weight | 58.32 g/mol |
| CAS number | 1309-42-8 |
| InChIKey | VTHJTEIRLNZDEV-UHFFFAOYSA-L |
| PubChem CID | 73981 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Magnesium hydroxide used for?
DrugCentral lists the following indications for Magnesium hydroxide: Constipation, Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn, Heartburn Prevention, Hiatal Hernia with Reflux Esophagitis, Incomplete passage of stool and Indigestion and others.
When was Magnesium hydroxide first approved?
Magnesium hydroxide was first approved by the FDA in 2000.
What is the chemical formula of Magnesium hydroxide?
Magnesium hydroxide has the molecular formula H2MgO2 and a molecular weight of 58.32 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4244 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200718 — compound record and bioactivity
- PubChem CID 73981 — chemical identifiers
- DrugBank DB09104 — drug record
- FDA UNII NBZ3QY004S — substance identity
- DailyMed: FDA labels for Magnesium hydroxide — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.